The stock of Galapagos NV (NASDAQ:GLPG) last traded at $37.16, up 0.87% from the previous session.
Data from the available sources indicates that Galapagos NV (NASDAQ:GLPG) is covered by 12 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $71.85 and a low of $37.35, we find $45.03. Given the previous closing price of $36.84, this indicates a potential upside of 22.23 percent. GLPG stock price is now -12.92% away from the 50-day moving average and -21.31% away from the 200-day moving average. The market capitalization of the company currently stands at $2.46B.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
In total, 10 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $48.96 as their price target over the next twelve months.
With the price target reduced from $49 to $47.20, Jefferies Upgraded its rating from Underperform to Hold for Galapagos NV (NASDAQ: GLPG). , while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
There have been several recent changes in the stakes of large investors in GLPG stock. A new stake in Galapagos NV shares was purchased by STONEPINE CAPITAL MANAGEMENT, LLC during the first quarter worth $7,240,000. BVF INC/IL invested $3,716,000 in shares of GLPG during the first quarter. In the first quarter, SUVRETTA CAPITAL MANAGEMENT, LLC acquired a new stake in Galapagos NV valued at approximately $1,754,000. CAPTION MANAGEMENT, LLC acquired a new stake in GLPG for approximately $929,000. SHAY CAPITAL LLC purchased a new stake in GLPG valued at around $743,000 in the second quarter. In total, there are 113 active investors with 19.60% ownership of the company’s stock.
With an opening price of $37.05 on Monday morning, Galapagos NV (NASDAQ: GLPG) set off the trading day. During the past 12 months, Galapagos NV has had a low of $36.20 and a high of $72.11. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 8.40, and a quick ratio of 8.30. The fifty day moving average price for GLPG is $42.67 and a two-hundred day moving average price translates $47.22 for the stock.
The latest earnings results from Galapagos NV (NASDAQ: GLPG) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at $0.35, beating analysts’ expectations of -$1.12 by 1.47. This compares to -$1.17 EPS in the same period last year. The net profit margin was -14.60% and return on equity was -3.00% for GLPG. The company reported revenue of $137.18 million for the quarter, compared to $75.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 81.23 percent. For the current quarter, analysts expect GLPG to generate $126.11M in revenue.
Galapagos NV(GLPG) Company Profile
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Leave a Reply